Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin thromboprophylaxis in high-risk outpatients with lung or gastrointestinal cancer starting anticancer therapy
ACTRN12618000811202Phase 3Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enoxaparin in thromboembolism (3 arms), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Objectively confirmed symptomatic or asymptomatic thromboembolism. Started Jun 2018; status: completed.
02
Drugs
enoxaparin
03
Conditions
thromboembolism
Beyond the preview
Go deeper on ACTRN12618000811202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000811202.